Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Green Cross HealthNZSE:GXH -0.25%63 Return-on-Tangible-Equity is 478.58% as of Mar. 2026, which is 50% above its 10-year median of 318.34. GuruFocus rates NZSE:GXH with a GF Score™ of 63/100 and a GF Value™ of NZ$1.08 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 575 Healthcare Providers & Services companies, Green Cross Health ranks better than 88.7% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Green Cross Health's annualized net income for the quarter that ended in Mar. 2026 was NZ$26.4 Mil. Green Cross Health's average shareholder tangible equity for the quarter that ended in Mar. 2026 was NZ$5.5 Mil. Therefore, Green Cross Health's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 478.58%.
The historical rank and industry rank for Green Cross Health's Return-on-Tangible-Equity or its related term are showing as below:
NZSE:GXH'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 95.16 Med: 318.34 Max: 109160
Current: 523.89
During the past 13 years, Green Cross Health's highest Return-on-Tangible-Equity was 109,160.00%. The lowest was 95.16%. And the median was 318.34%.
NZSE:GXH's Return-on-Tangible-Equity is ranked better than 88.7% of 575
companies
in the Healthcare Providers & Services industry
Industry Median: 10.45
vs NZSE:GXH: 523.89
Green Cross Health (NZSE:GXH) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Green Cross Health Return-on-Tangible-Equity Related Terms
Green Cross Health Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Green Cross Health's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Green Cross Health Return-on-Tangible-Equity Chart
Green Cross Health Return-on-Tangible-Equity Competitor Comparison
For the Pharmaceutical Retailers subindustry, Green Cross Health's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Green Cross Health Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Green Cross Health's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Green Cross Health's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 478.58% mean?
Green Cross Health (NZSE:GXH) has a Return-on-Tangible-Equity of 478.58% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Green Cross Health and its competitors. This is 50% above median its historical median of 318.34. Over the past decade, Green Cross Health's Return-on-Tangible-Equity has ranged from 95.16 to 109,160.00. According to the industry distribution chart, Green Cross Health ranks #65 out of 575 companies in the Healthcare Providers & Services industry, placing it in the top 11.3%.
Is Green Cross Health's Return-on-Tangible-Equity too high?
Green Cross Health's current Return-on-Tangible-Equity of 478.58% is 50% above median its 10-year median of 318.34. Over the past 10 years, this metric has ranged from a low of 95.16 to a high of 109,160.00. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.45. Green Cross Health's value of 478.58% is 4479.7% above this industry median. Based on the distribution chart, Green Cross Health ranks #65 out of 575 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Green Cross Health has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Green Cross Health's Return-on-Tangible-Equity compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Green Cross Health ranks #65 out of 575 companies for Return-on-Tangible-Equity. This places Green Cross Health in the top 11% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 10.45. Green Cross Health's value of 478.58% is 4479.7% above this benchmark. Historically, Green Cross Health's own Return-on-Tangible-Equity has ranged from 95.16 to 109,160.00 over the past decade. While the company's 10-year median is 318.34 vs. the industry median of 10.45, Green Cross Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.45, based on 575 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Green Cross Health's current Return-on-Tangible-Equity of 478.58% is 4479.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Green Cross Health and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Green Cross Health's current Return-on-Tangible-Equity is 478.58%, which is 50% above median its own 10-year median of 318.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Green Cross Health stock overvalued right now?
Based on GuruFocus' analysis, Green Cross Health (NZSE:GXH) is currently considered Significantly Overvalued. The stock's GF Value™ is NZ$1.08, compared to a current price of NZ$1.96 — trading 81.5% above its estimated fair value. The current Return-on-Tangible-Equity is 478.58%, which is 50% above median its 10-year median of 318.34 and 4479.7% above the Healthcare Providers & Services industry median of 10.45. Green Cross Health's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Green Cross Health (NZSE:GXH), the current Return-on-Tangible-Equity is 478.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Green Cross Health (NZSE:GXH) Overvalued in 2026?
Based on GuruFocus' analysis, Green Cross Health stock appears to be overvalued.
The current stock price of NZ$1.96 is trading 81.5% above its estimated GF Value™ of NZ$1.08.
GuruFocus considers Green Cross Health to be Significantly Overvalued.
Key valuation signals for NZSE:GXH:
Return-on-Tangible-Equity: 478.58% (50% above median its 10-year median of 318.34)
GF Value™: NZ$1.08 vs. price of NZ$1.96 (81.5% above fair value)
Industry Position: 4479.7% above the Healthcare Providers & Services median (#65 of 575)
No single metric tells the full story. See the NZSE:GXH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Green Cross Health Ltd is engaged in providing healthcare services in New Zealand. The reportable segments of the group are Pharmacy services and medical services. The majority of the revenue is generated from the Pharmacy services segment. The pharmacy services segment provides retail and dispensary services, and the medical services segment provides GP, nursing, and urgent care services. The majority of its revenue is generated from the pharmacy segment.
63GF Score
Get the complete analysis for NZSE:GXH
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:GXH has been successfully added to your 
